Skandinaviska Enskilda Banken (SEB)
XERS icon

Skandinaviska Enskilda Banken (SEB)’s Xeris Biopharma Holdings XERS Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,000
Closed -$204K – 837
2025
Q3 		$204K Buy
+25,000
New +$166K ﹤0.01% 709

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s XERS Position: Q4 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 25,000 shares — an estimated $204K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in XERS in Q3 2025 and held it in 1 quarter. The position peaked at $204K in Q3 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 25,000 Xeris Biopharma Holdings shares in Q4 2025, an estimated $204K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Xeris Biopharma Holdings in Q3 2025 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Xeris Biopharma Holdings position peaked at $204K in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2025, filed 12 Feb 2026.